84 related articles for article (PubMed ID: 27272299)
1. Authors' reply re: Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
de Kok IM; van Rosmalen J; van Ballegooijen M
BJOG; 2016 Jul; 123(8):1401-2. PubMed ID: 27272299
[No Abstract] [Full Text] [Related]
2. Re: Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
Chung SH; Kim TH; Lee HH; Kim JM; Kim YS
BJOG; 2016 Jul; 123(8):1400-1. PubMed ID: 27272298
[No Abstract] [Full Text] [Related]
3. Authors' reply re: Reflex cytology for triage of high-risk human-papillomavirus-positive self-sampled material in cervical cancer screening: a prospective cohort study.
Loopik DL; Melchers WJ; Vedder JE; van den Brule AJ; Massuger LF; Bekkers RL; Siebers AG
BJOG; 2020 Dec; 127(13):1714-1715. PubMed ID: 32864828
[No Abstract] [Full Text] [Related]
4. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
[TBL] [Abstract][Full Text] [Related]
5. Assessing the diagnostic value of Xpert HPV - Authors' reply.
Kuhn L; Saidu R; Denny L
Lancet Glob Health; 2020 Aug; 8(8):e998. PubMed ID: 32710877
[No Abstract] [Full Text] [Related]
6. The health and economic effects of HPV DNA screening in The Netherlands.
Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
[TBL] [Abstract][Full Text] [Related]
7. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
Ting J; Smith JS; Myers ER
J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
[TBL] [Abstract][Full Text] [Related]
9. [Cervical cancer--possibilities of detection of human papillomavirus].
Ondryášová H; Koudeláková V; Hajdúch M
Ceska Gynekol; 2013 Jun; 78(3):289-94. PubMed ID: 23869837
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.
Schiffman M; Solomon D
N Engl J Med; 2013 Dec; 369(24):2324-31. PubMed ID: 24328466
[No Abstract] [Full Text] [Related]
12. Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china.
Valdez M; Jeronimo J; Bansil P; Qiao YL; Zhao FH; Chen W; Zhang X; Kang LN; Paul P; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
Int J Cancer; 2016 Mar; 138(6):1453-61. PubMed ID: 26421807
[TBL] [Abstract][Full Text] [Related]
13. Cancer screening of the uterine cervix papanicolaou smears versus state-of-the-art human papillomavirus testing.
Knight B
Cancer Cytopathol; 2012 Apr; 120(2):105-7. PubMed ID: 22367779
[TBL] [Abstract][Full Text] [Related]
14. Can the test for human papillomavirus DNA be used as the stand-alone, first-line screening test for cervical cancer?
Jin XW; McKenzie ML; Yen-Lieberman B
Cleve Clin J Med; 2015 Apr; 82(4):213-5. PubMed ID: 25955454
[No Abstract] [Full Text] [Related]
15. Human papillomavirus detection: verification with cervical cytology.
Matthews-Greer J; Rivette D; Reyes R; Vanderloos CF; Turbat-Herrera EA
Clin Lab Sci; 2004; 17(1):8-11. PubMed ID: 15011974
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and follow-up patient groups.
Yeoh GP; Tse MP; Chan KW; Lord L
Acta Cytol; 2006; 50(6):627-31. PubMed ID: 17152273
[TBL] [Abstract][Full Text] [Related]
17. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
18. [Screening of cervical cancer and test for HPV].
Hirai Y
Gan To Kagaku Ryoho; 2010 Feb; 37(2):232-5. PubMed ID: 20235390
[No Abstract] [Full Text] [Related]
19. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.
Nishino HT; Tambouret RH; Wilbur DC
Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588
[TBL] [Abstract][Full Text] [Related]
20. Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening.
Herbert A
Cytopathology; 2017 Feb; 28(1):9-15. PubMed ID: 27005867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
